Covered recipient · General Payments record
JOHN C PARKER
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$21,819.25
251 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $8,450.00 | 5 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,800.00 | 6 |
| Food and Beverage | $3,520.12 | 229 |
| Honoraria | $2,000.00 | 1 |
| Travel and Lodging | $985.80 | 1 |
| Education | $63.33 | 9 |
By paying entity
PY2019 · entire year · sorted by reported total
Page 6 of 6; records 251–251 of 251 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JOHN C PARKER
NPI 1457345928 · CMS profile ID 111752
Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism
WILMINGTON, NC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 6 of 6; records 251–251 of 251 matching records. This page contains 1 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1457345928?year=2019&recipient=provider&page=6#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JOHN C PARKER, NPI 1457345928, CMS profile ID 111752. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–251 of 251 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457345928?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). JOHN C PARKER, NPI 1457345928, CMS profile ID 111752. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–251 of 251 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457345928?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- JOHN C PARKER, NPI 1457345928, CMS profile ID 111752, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 6; records 251–251 of 251 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1457345928?year=2019&recipient=provider&page=6#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
251 matching records · $21,819.25 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 251–251 of 251.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corporation | $8.23 | 01/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695205119 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,283.60 | 7 |
| PY2025 | Principal investigator | $1,754,233.74 | 60 |
| PY2024 | Recipient | $35,760.20 | 6 |
| PY2024 | Principal investigator | $615,212.88 | 39 |
| PY2023 | Recipient | $834.01 | 1 |
| PY2023 | Principal investigator | $135,727.02 | 32 |
| PY2022 | Recipient | $530.00 | 1 |
| PY2022 | Principal investigator | $246,139.52 | 36 |
| PY2021 | Recipient | $1,623.24 | 4 |
| PY2021 | Principal investigator | $596,905.04 | 313 |
| PY2020 | Recipient | $1,480.28 | 5 |
| PY2020 | Principal investigator | $355,554.95 | 61 |
| PY2019 | Principal investigator | $212,752.19 | 94 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
67 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $5,587.00 | 12/31/2025 | Non-covered Recipient Entity PMG RESEARCH INC | A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism | No dispute reported | 06/30/2026 | 1202534587 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $449.60 | 12/31/2025 | Non-covered Recipient Entity PMG Research of Wilmington | A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control | No dispute reported | 06/30/2026 | 1232918019 |
| Principal investigator 1 | Insulet Corporation | $1,000.00 | 12/17/2025 | Non-covered Recipient Entity ACCELLACARE | Feasibility of Simplified Onboarding in Adults with Type 2 Diabetes using Automated Insulin Delivery | No dispute reported | 06/30/2026 | 1206962116 |
| Principal investigator 1 | ABBVIE INC. | $48,629.70 | 12/05/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202529298 |
| Principal investigator 1 | TOLMAR, INC. | $132.30 | 11/20/2025 | Non-covered Recipient Entity ACCELLACARE US INC | TOL-CLAR-20024 | No dispute reported | 06/30/2026 | 1237323287 |
| Principal investigator 1 | TOLMAR, INC. | $81.00 | 11/20/2025 | Non-covered Recipient Entity ACCELLACARE US INC | TOL-CLAR-20024 | No dispute reported | 06/30/2026 | 1237323291 |
| Principal investigator 1 | Insulet Corporation | $3,235.00 | 11/19/2025 | Non-covered Recipient Entity ACCELLACARE | Feasibility of Simplified Onboarding in Adults with Type 2 Diabetes using Automated Insulin Delivery | No dispute reported | 06/30/2026 | 1206961976 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,000.00 | 11/11/2025 | Non-covered Recipient Entity Accellacare | A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a | No dispute reported | 06/30/2026 | 1225415408 |
| Principal investigator 1 | TOLMAR, INC. | $3,769.20 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | TOL-CLAR-20024 | No dispute reported | 06/30/2026 | 1237323273 |
| Principal investigator 1 | TOLMAR, INC. | $1,549.80 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | TOL-CLAR-20024 | No dispute reported | 06/30/2026 | 1237323276 |
| Principal investigator 1 | TOLMAR, INC. | $602.10 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | TOL-CLAR-20024 | No dispute reported | 06/30/2026 | 1237323279 |
| Principal investigator 1 | TOLMAR, INC. | $1,204.20 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | TOL-CLAR-20024 | No dispute reported | 06/30/2026 | 1237323283 |
| Principal investigator 1 | ABBVIE INC. | $56,137.05 | 11/05/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202522541 |
| Principal investigator 1 | PFIZER INC. | $20,305.21 | 11/04/2025 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228724014 |
| Principal investigator 1 | ABBVIE INC. | $30,898.80 | 10/09/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202514365 |
| Principal investigator 1 | Insulet Corporation | $1,425.00 | 09/24/2025 | Non-covered Recipient Entity ACCELLACARE | Feasibility of Simplified Onboarding in Adults with Type 2 Diabetes using Automated Insulin Delivery | No dispute reported | 06/30/2026 | 1206961897 |
| Principal investigator 1 | PFIZER INC. | $7,069.89 | 09/24/2025 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228757552 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $500.00 | 09/09/2025 | Non-covered Recipient Entity Accellacare | A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a | No dispute reported | 06/30/2026 | 1225414712 |
| Principal investigator 1 | ABBVIE INC. | $52,957.80 | 09/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202509478 |
| Principal investigator 1 | Eli Lilly and Company | $67,339.00 | 09/02/2025 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBSTRUCTIVE SLEEP APNEA AND OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL | No dispute reported | 06/30/2026 | 1187888960 |
| Principal investigator 1 | PFIZER INC. | $9,926.37 | 08/26/2025 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228786837 |
| Principal investigator 1 | ABBVIE INC. | $81,881.55 | 08/06/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202503239 |
| Principal investigator 1 | PFIZER INC. | $7,775.63 | 08/05/2025 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228766785 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,723.00 | 07/31/2025 | Non-covered Recipient Entity Accellacare | A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a | No dispute reported | 06/30/2026 | 1225412932 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,458.00 | 07/31/2025 | Non-covered Recipient Entity Accellacare | A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a | No dispute reported | 06/30/2026 | 1225413182 |
| Principal investigator 1 | PFIZER INC. | $350.00 | 07/18/2025 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228764986 |
| Principal investigator 1 | PFIZER INC. | $12,209.59 | 07/15/2025 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228724308 |
| Principal investigator 1 | ABBVIE INC. | $27,278.10 | 07/02/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202495219 |
| Principal investigator 1 | PFIZER INC. | $22,339.83 | 06/26/2025 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228776545 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,903.00 | 06/19/2025 | Non-covered Recipient Entity Accellacare | A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a | No dispute reported | 06/30/2026 | 1225412436 |
| Principal investigator 1 | Eli Lilly and Company | $5.33 | 06/16/2025 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBSTRUCTIVE SLEEP APNEA AND OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL | No dispute reported | 06/30/2026 | 1187889512 |
| Principal investigator 1 | TOLMAR, INC. | $6,909.30 | 06/12/2025 | Non-covered Recipient Entity ACCELLACARE US INC | TOL-CLAR-20024 | No dispute reported | 06/30/2026 | 1237323195 |
| Principal investigator 1 | ABBVIE INC. | $40,387.95 | 06/03/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202488147 |
| Principal investigator 1 | TOLMAR, INC. | $3,000.00 | 05/15/2025 | Non-covered Recipient Entity ACCELLACARE US INC | TOL-CLAR-20024 | No dispute reported | 06/30/2026 | 1237323186 |
| Principal investigator 1 | TOLMAR, INC. | $1,350.00 | 05/15/2025 | Non-covered Recipient Entity ACCELLACARE US INC | TOL-CLAR-20024 | No dispute reported | 06/30/2026 | 1237323191 |
| Principal investigator 1 | PFIZER INC. | $36,264.40 | 05/14/2025 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228781749 |
| Principal investigator 1 | ABBVIE INC. | $28,540.35 | 05/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202483093 |
| Principal investigator 1 | PFIZER INC. | $62,298.32 | 05/03/2025 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228782515 |
| Recipient | Corcept Therapeutics | $59.00 | 05/02/2025 | Covered Recipient Physician | COR311 | No dispute reported | 06/30/2026 | 1214162966 |
| Recipient | Corcept Therapeutics | $71.74 | 05/02/2025 | Covered Recipient Physician | COR311 | No dispute reported | 06/30/2026 | 1214162974 |
| Recipient | Corcept Therapeutics | $76.44 | 05/02/2025 | Covered Recipient Physician | COR311 | No dispute reported | 06/30/2026 | 1214162978 |
| Recipient | Corcept Therapeutics | $98.62 | 05/02/2025 | Covered Recipient Physician | COR311 | No dispute reported | 06/30/2026 | 1214162983 |
| Recipient | Corcept Therapeutics | $32.67 | 05/02/2025 | Covered Recipient Physician | COR311 | No dispute reported | 06/30/2026 | 1214162987 |
| Recipient | Corcept Therapeutics | $573.36 | 05/01/2025 | Covered Recipient Physician | COR311 | No dispute reported | 06/30/2026 | 1214162962 |
| Recipient | Corcept Therapeutics | $371.77 | 05/01/2025 | Covered Recipient Physician | COR311 | No dispute reported | 06/30/2026 | 1214162970 |
| Principal investigator 1 | TOLMAR, INC. | $7,688.25 | 04/08/2025 | Non-covered Recipient Entity ACCELLACARE US INC | TOL-CLAR-20024 | No dispute reported | 06/30/2026 | 1237323182 |
| Principal investigator 1 | ABBVIE INC. | $23,656.05 | 04/03/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202473132 |
| Principal investigator 1 | TOLMAR, INC. | $4,179.60 | 04/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | TOL-CLAR-20024 | No dispute reported | 06/30/2026 | 1237323173 |
| Principal investigator 1 | TOLMAR, INC. | $1,094.85 | 04/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | TOL-CLAR-20024 | No dispute reported | 06/30/2026 | 1237323177 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $7,079.00 | 03/27/2025 | Non-covered Recipient Entity Accellacare | BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney | No dispute reported | 06/30/2026 | 1225403889 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $123.00 | 03/13/2025 | Non-covered Recipient Entity Accellacare | BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney | No dispute reported | 06/30/2026 | 1225403887 |
| Principal investigator 1 | ABBVIE INC. | $28,595.70 | 03/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202460641 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $9,626.00 | 03/06/2025 | Non-covered Recipient Entity Accellacare | BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney | No dispute reported | 06/30/2026 | 1225403455 |
| Principal investigator 1 | ABBVIE INC. | $33,280.20 | 02/06/2025 | Non-covered Recipient Entity ACCELLACARE US INC | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202448019 |
| Principal investigator 1 | Eli Lilly and Company | $2,073.62 | 01/31/2025 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187887248 |
| Principal investigator 1 | Eli Lilly and Company | $1,352.40 | 01/31/2025 | Non-covered Recipient Entity RHEUMATOLOGY CENTER OF HOUSTON | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) | No dispute reported | 06/30/2026 | 1187887788 |
| Principal investigator 1 | Eli Lilly and Company | $570.00 | 01/31/2025 | Non-covered Recipient Entity RHEUMATOLOGY CENTER OF HOUSTON | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBSTRUCTIVE SLEEP APNEA AND OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL | No dispute reported | 06/30/2026 | 1187889544 |
| Principal investigator 1 | Eli Lilly and Company | $564,545.00 | 01/28/2025 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY | No dispute reported | 06/30/2026 | 1187889502 |
| Principal investigator 1 | Eli Lilly and Company | $5,161.39 | 01/27/2025 | Non-covered Recipient Entity RHEUMATOLOGY CENTER OF HOUSTON | A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY | No dispute reported | 06/30/2026 | 1187887444 |
| Principal investigator 1 | Eli Lilly and Company | $1,152.15 | 01/27/2025 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187888958 |
| Principal investigator 1 | Eli Lilly and Company | $1,470.16 | 01/27/2025 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF INVESTIGATIONAL TIRZEPATIDE DOSES IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY | No dispute reported | 06/30/2026 | 1187889506 |
| Principal investigator 1 | Eli Lilly and Company | $154,192.00 | 01/21/2025 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) | No dispute reported | 06/30/2026 | 1187889100 |
| Principal investigator 1 | Eli Lilly and Company | $38,404.00 | 01/21/2025 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF INVESTIGATIONAL TIRZEPATIDE DOSES IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY | No dispute reported | 06/30/2026 | 1187890462 |
| Principal investigator 1 | PFIZER INC. | $156.00 | 01/15/2025 | Non-covered Recipient Entity ACCELLACARE WILMINGTON | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228734354 |
| Principal investigator 1 | Eli Lilly and Company | $41,626.00 | 01/07/2025 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187887500 |
| Principal investigator 1 | Eli Lilly and Company | $135,572.00 | 01/07/2025 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187887504 |
| Principal investigator 1 | Eli Lilly and Company | $42,163.00 | 01/07/2025 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187888792 |